Chemical industry – Page 87
-
-
Business
Evotec moves business back to UK
Pharma company closes operations in India, citing distance from customers
-
Business
Biosimilar drugs step up complexity
First generic monoclonal antibodies recommended for approval in Europe
-
OpinionTarget acquired
Knowing a drug’s exact biochemistry has never been a prerequisite for approval, says Derek Lowe, and nor should it be
-
Business
Sluggish recovery for European chemical sector
Industry body predicts second consecutive yearly drop in output with growth not expected to start again until 2014
-
Business
Aspen in $1 billion deal with Merck & Co
South African generics manufacturer to buy 11 drug brands and an API business from the US drugmaker
-
Business
Data-sharing partnership for drug discovery
Collaborative project aims to assist medicinal chemistry efforts
-
Business
UK government to boost shale gas industry
Plans to invest in shale gas follow reports of vast reserves in the north of England
-
Business
Ups and downs for erectile dysfunction drugs
First new drug in a decade approved in Europe as Viagra patent expires
-
Business
NHS to offer breast cancer prevention drugs
Five-year course of tamoxifen or raloxifene recommended for high risk women
-
CareersGoing with the flow chemistry
Elizabeth Farrant climbed to the top in big pharma, but now she’s working at a smaller scale, as Sarah Houlton finds out
-
-
BusinessAstraZeneca announces new UK hub
Restructuring will see all AstraZeneca R&D at new location close to University of Cambridge research
-
Business
Companies urged to publish hidden clinical trial data
Researchers could acquire data and publish themselves if firms refuse
-
Business
GSK fires Chinese R&D head in data investigation
Company is retracting a 2010 study in which data were ‘misrepresented’
-
Business
Pfizer and Takeda win $2.15bn in patent payout
Teva and Sun fined for selling generics before patent expiry
-
Business
Big data to sniff out drug marketing fraud
US Food and Drug Administration wants to track promotional spending to spot off-label marketing